nach oben

International Journal of Clinical Oncology

Erschienen in:

11.07.2016 | Original Article

The impact of body mass index on oncological outcomes in colorectal cancer patients with curative intent

verfasst von: Yuji Toiyama, Junichiro Hiro, Tadanobu Shimura, Hiroyuki Fujikawa, Masaki Ohi, Koji Tanaka, Yasuhiro Inoue, Yasuhiko Mohri, Masato Kusunoki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Excess body weight is associated with a risk of several malignancies, including colon cancer. However, the oncological significance of evaluating body mass index (BMI) preoperatively in colorectal cancer (CRC) patients undergoing curative surgery has not been fully evaluated.

Methods

Clinicopathological findings including BMI and laboratory data [carcinoembryonic antigen (CEA) and neutrophil/lymphocyte ratio (NLR)] from 358 curative CRC patients (open surgery group: n = 157; laparoscopic surgery group: n = 201) were assessed as indicators of survival outcome. BMI <20 was defined as underweight in both groups.

Results

Not all categories of pathological findings were associated with BMI in both groups. Patients with BMI <20 showed significant poorer overall survival (OS) in the open surgery group. In addition, patients with BMI <20 in the laparoscopic surgery group were also significantly worse in OS and disease-free survival (DFS). Furthermore, multivariate analysis demonstrated that BMI was validated as independent predictors for OS and DFS in both groups. BMI had a significant negative correlation with NLR, which reflects host immune response in both groups.

Conclusions

Lower BMI is a promising predictor of recurrence and prognosis in curative CRC patients.

Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRefPubMed

Gilbert CA, Slingerland JM (2013) Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 64:45–57CrossRefPubMed

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591CrossRefPubMed

Matsuda M, Shimomura I (2013) Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 7:e330–e341CrossRefPubMed

Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (Phila) 118:5937–5946CrossRef

Ho T, Gerber L, Aronson WJ et al (2012) Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol 62:910–916CrossRefPubMedPubMedCentral

Leroy J, Ananian P, Rubino F et al (2005) The impact of obesity on technical feasibility and postoperative outcomes of laparoscopic left colectomy. Ann Surg 241:69–76PubMedPubMedCentral

Nitori N, Hasegawa H, Ishii Y et al (2009) Impact of visceral obesity on short-term outcome after laparoscopic surgery for colorectal cancer: a single Japanese center study. Surg Laparosc Endosc Percutan Tech 19:324–327CrossRefPubMed

Park JW, Lim SW, Choi HS et al (2010) The impact of obesity on outcomes of laparoscopic surgery for colorectal cancer in Asians. Surg Endosc 24:1679–1685CrossRefPubMed

10.

Schwandner O, Farke S, Schiedeck TH et al (2004) Laparoscopic colorectal surgery in obese and nonobese patients: do differences in body mass indices lead to different outcomes? Surg Endosc 18:1452–1456CrossRefPubMed

11.

Lascano CA, Kaidar-Person O, Szomstein S et al (2006) Challenges of laparoscopic colectomy in the obese patient: a review. Am J Surg 192:357–365CrossRefPubMed

12.

Takeuchi K, Kuwano H, Tsuzuki Y et al (2004) Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum. Hepatogastroenterology 51:1698–1702PubMed

13.

Sugao Y, Yao T, Kubo C et al (1997) Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study. Histopathology (Oxf) 31:123–133CrossRef

14.

Hyngstrom JR, Hu CY, Xing Y et al (2012) Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 19:2814–2821CrossRefPubMedPubMedCentral

15.

Giakoustidis A, Neofytou K, Khan AZ et al (2015) Neutrophil to lymphocyte ratio predicts pattern of recurrence in patients undergoing liver resection for colorectal liver metastasis and thus the overall survival. J Surg Oncol 111:445–450CrossRefPubMed

16.

Chang Z, Zheng J, Ma Y et al (2014) The neutrophil-to-lymphocyte ratio as a predictor for recurrence of colorectal liver metastases following radiofrequency ablation. Med Oncol 31:855CrossRefPubMed

17.

Shibutani M, Maeda K, Nagahara H et al (2013) A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 33:3291–3294PubMed

18.

Kalantar-Zadeh K, Horwich TB, Oreopoulos A et al (2007) Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 10:433–442CrossRefPubMed

19.

Flegal KM, Kit BK, Orpana H et al (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71–82CrossRefPubMedPubMedCentral

20.

Hakimi AA, Furberg H, Zabor EC et al (2013) An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 105:1862–1870CrossRefPubMedPubMedCentral

21.

Sinicrope FA, Foster NR, Yothers G et al (2013) Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer (Phila) 119:1528–1536CrossRef

22.

Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis (Oxf) 33:949–955CrossRef

23.

Fridman WH, Pages F, Sautes-Fridman C et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306CrossRefPubMed

24.

Wein A, Hahn EG, Merkel S et al (2000) Adjuvant chemotherapy for stage II (Dukes’ B) colon cancer: too early for routine use. Eur J Surg Oncol 26:730–732CrossRefPubMed

25.

Haller DG (1995) An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 31A:1255–1263CrossRefPubMed

26.

Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419CrossRefPubMed

27.

Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516CrossRefPubMed

Titel: The impact of body mass index on oncological outcomes in colorectal cancer patients with curative intent
verfasst von: Yuji Toiyama
Junichiro Hiro
Tadanobu Shimura
Hiroyuki Fujikawa
Masaki Ohi
Koji Tanaka
Yasuhiro Inoue
Yasuhiko Mohri
Masato Kusunoki
Publikationsdatum: 11.07.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1016-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The impact of body mass index on oncological outcomes in colorectal cancer patients with curative intent